All In Biotech

Drug Trial Radar · NCT03580356

A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

Last checked: Nov 20, 2026Latest source record: Jan 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,078 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,078

Actual

Start

Oct 20, 2018

Primary completion

Jun 22, 2021

Study completion Jun 14, 2022

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jul 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to establish efficacy and safety of ligelizumab in adolescent and adult subjects with CSU who remained symptomatic despite standard of care treatment by demonstrating better efficacy over omalizumab and over placebo. The study population consisted of 1,079 male and female subjects aged ≥ 12 years who were diagnosed with CSU and who remained symptomatic despite the use of H1-antihistamines. This was a multi-center, randomized, double-blind, active- and placebo-controlled, parallel-group study. There was a screening period of up to 28 days, a 52 week double-blind treatment period, and a 12 week post-treatment follow-up period.

Conditions

  • Chronic Spontaneous Urticaria

Interventions

  • LigelizumabBiological

    Liquid in vial

  • OmalizumabBiological

    Lyophilized powder for solution in vial

  • PlaceboOther

    Liquid in vial

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in UAS7 at Week 12 (Multiple Imputation) of Adult SubjectsTime frame: Baseline, Week 12
  2. Mean Change From Baseline in UAS7 at Week 12 (Observed Data) of Adolescent Subjects (FAS)Time frame: Baseline, Week 12

Locations

183 sites in 27 countries. Site status is shown where the registry gives one.

  • Allervie Clinical Research

    Birmingham, Alabama

  • Medical Resch of Arizona-Div of Allergy Asthma and Immunology

    Scottsdale, Arizona

  • Atria Clinical Research Asthma and Allergy Institute

    Little Rock, Arkansas

  • DeMera Allergy Asthma and Immun Ctr

    Fresno, California

  • California Allergy and Asthma Medical Group

    Los Angeles, California

  • Jonathan Corren Inc

    Los Angeles, California

  • Allergy and Asthma Consultants

    Redwood City, California

  • Allergy and Asthma Associates of Santa Clara Vally Center

    San Jose, California

  • Sarasota Clinical Research

    Sarasota, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • Idaho Research

    Eagle, Idaho

  • Midwest Allergy Sinus Asthma SC

    Normal, Illinois

  • John Hopkins University

    Baltimore, Maryland

  • Institute for Asthma and Allergy PC

    Chevy Chase, Maryland

  • Chesapeake Clinical Research

    White Marsh, Maryland

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Midwest Clinical Research LcLC

    St Louis, Missouri

  • Montana Medical Research

    Missoula, Montana

  • The Asthma and Allergy Center PC

    Papillion, Nebraska

  • Icahn School Of Med At Mount Sinai

    New York, New York

  • Toledo Institute of Clinical Research

    Toledo, Ohio

  • Allergy Asthma and Clinical Research

    Oklahoma City, Oklahoma

  • PCR DBA Columbia Asthma and Allergy

    Clackamas, Oregon

  • Allergy and Asthma Specialists PC

    Blue Bell, Pennsylvania

  • Allergy and Clinical Immunology Associates

    Pittsburgh, Pennsylvania

  • National Allergy and Asthma Research LLS

    North Charleston, South Carolina

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • Western Sky Medical Research

    El Paso, Texas

  • North Texas Inst For Clinical Tri

    Fort Worth, Texas

  • Allergy and Asthma Research Center PA

    San Antonio, Texas

  • Quality Assurance Research Center

    San Antonio, Texas

  • Allergy and Asthma Care of Waco

    Waco, Texas

  • Allergy Associates of Utah

    Sandy City, Utah

  • Bellingham Asthma Allergy and Immunology

    Bellingham, Washington

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Salta, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mendoza, Mendoza Province, Argentina

Showing 40 of 183 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.